

May 15, 2026

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai- 400001 <b>Scrip Code</b> - 543308 <b>ISIN:</b> INE967H01025	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 <b>Symbol</b> - KIMS <b>ISIN:</b> INE967H01025
--	--

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on May 15, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Further to our intimation dated May 06, 2026, the Board of Directors, at its meeting held today, has approved the audited (Standalone and Consolidated) financial results of the Company for the quarter and financial year ended 31<sup>st</sup> March 2026.

As required by the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose/furnish the following particulars:

**1. Financials & Audit Reports:**

- i. Audited standalone financial results of the Company for the quarter and financial year ended 31<sup>st</sup> March 2026, along with the Audit Report on the standalone financial statement.
- ii. Audited consolidated financial results of the Company for the quarter and financial year ended 31<sup>st</sup> March 2026, along with the Audit Report on the consolidated financial statement.
- iii. The report of S.R. Batliboi & Associates LLP, Statutory Auditors of the Company, with an unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2026.

The audited financial results and audit reports (standalone & consolidated) along with the annexures therewith are enclosed as "**Annexure-1**".

2. **Appointment of Cost Auditors:** Pursuant to the recommendation made by the Audit Committee in their meeting held on 15, May, 2026, the Board of Directors have appointed M/s. Sagar & Associates, Cost Accountants as Cost Auditors for FY 2026-27 to audit the cost records of the Company and also recommended their remuneration for the approval of members in the ensuing AGM.

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as "**Annexure-2**".

3. **Appointment of Senior Management Personnel (SMP):** Based on the recommendation of the Nomination & Remuneration Committee meeting held on May, 15, 2026, the following personnel's of the Company are identified under Senior Management Personnel of the Company with immediate effect.

Sr. No	Name of the Person	Designation
1.	Mr. Sachin Ashok Salvi	Chief Finance Officer
2.	Mrs. Nagajayanthi J.R	Company Secretary & Compliance Officer
3.	Mr. Bhaskar Reddy R. K	Chief Risk Officer & Chief Internal Audit

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as "**Annexure-3**".

4. **Re-designation of Mr. Adwik Bollineni from Non-Executive & Non- Independent Director to Executive & Non Independent Director of the Company:** Based on the recommendation of the Nomination & Remuneration Committee held on May, 15, 2026, the Board of Directors has approved the re-designation of Mr. Adwik Bollineni from Non-Executive Director to Executive Director of the Company.

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as "**Annexure-3**".

5. **Annual General Meeting (AGM):** The 24<sup>th</sup> Annual General Meeting of the Company will be held on Thursday, 27<sup>th</sup> August 2026.

Further, the financial results are also available on the website of the Company at [https://www.kimshospitals.com/investors/Disclosures\\_under\\_Regulation\\_46\\_of\\_SEBI\\_\(LODR\)\\_Regulations\\_2015/Financial\\_Information/Financial\\_Result](https://www.kimshospitals.com/investors/Disclosures_under_Regulation_46_of_SEBI_(LODR)_Regulations_2015/Financial_Information/Financial_Result) and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com), respectively.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

**Board Meeting Commenced at** : 02.00 P.M.

**Board Meeting Concluded at** : 05:00 P.M.

This is for your information and records.

Thanking you,

**For Krishna Institute of Medical Sciences Limited**

**Nagajayanthi J.R**

**Company Secretary & Compliance Officer**

Enclosed: As above

**S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

THE SKYVIEW 10  
18th Floor, "NORTH LOBBY"  
Survey No. 83/1, Raidurgam  
Hyderabad - 500 032, India  
Tel : +91 40 6141 6000

**Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
Krishna Institute of Medical Sciences Limited

**Report on the audit of the Standalone Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended March 31, 2026 and for the year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



## **Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## **Other Matter**

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004



per Navneet Rai Kabra  
Partner

Membership No.: 102328

UDIN: 261023280Q8X4N2099

Place: Hyderabad

Date: May 15, 2026



**Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2026**

(Rupees in millions)

		Quarter ended			Year ended	
		31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
		(Audited) (Refer note 2)	(Unaudited)	(Audited) (Refer note 2)	(Audited)	(Audited)
1	<b>Income</b>					
	(a) Revenue from operations	4,562	4,419	3,459	17,015	13,841
	(b) Other income	176	143	242	566	567
	<b>Total Income</b>	<b>4,738</b>	<b>4,562</b>	<b>3,701</b>	<b>17,581</b>	<b>14,408</b>
2	<b>Expenses</b>					
	(a) Purchase of medical consumables, drugs and surgical instruments	910	860	707	3,468	2,795
	(b) (Increase)/decrease in inventories of medical consumables, drugs and surgical instruments	(4)	(45)	6	(135)	(42)
	(c) Employee benefits expense	720	744	582	2,907	2,364
	(d) Other expenses	1,631	1,583	1,077	6,096	4,559
	(e) Finance costs	268	216	81	787	232
	(f) Depreciation and amortisation expenses	255	226	151	861	577
	<b>Total Expenses</b>	<b>3,780</b>	<b>3,584</b>	<b>2,604</b>	<b>13,984</b>	<b>10,485</b>
3	<b>Profit before tax and exceptional items (1-2)</b>	<b>958</b>	<b>978</b>	<b>1,097</b>	<b>3,597</b>	<b>3,923</b>
4	<b>Exceptional items</b>	<b>(67)</b>	<b>-</b>	<b>108</b>	<b>(70)</b>	<b>108</b>
5	<b>Profit before tax (3+4)</b>	<b>891</b>	<b>978</b>	<b>1,205</b>	<b>3,527</b>	<b>4,031</b>
6	<b>Tax expense</b>					
	(a) Current tax	182	202	204	745	951
	(b) Deferred tax charge	50	51	66	175	51
	<b>Total tax expenses</b>	<b>232</b>	<b>253</b>	<b>270</b>	<b>920</b>	<b>1,002</b>
7	<b>Profit for the period/year (5-6)</b>	<b>659</b>	<b>725</b>	<b>935</b>	<b>2,607</b>	<b>3,029</b>
8	<b>Other comprehensive income/(loss) for the period/year</b>					
	Items that will not be reclassified subsequently to statement of profit and loss					
	- Re-measurement gain/(loss) on defined benefit plans	2	-	10	0	(18)
	- Income tax effect	(1)	-	(2)	(0)	5
	<b>Other comprehensive income/(loss), net of tax</b>	<b>1</b>	<b>-</b>	<b>8</b>	<b>0</b>	<b>(13)</b>
9	<b>Total comprehensive income for the period/year (7+8)</b>	<b>660</b>	<b>725</b>	<b>943</b>	<b>2,607</b>	<b>3,016</b>
10	<b>Paid up equity share capital (face value of Rs.2 each)</b>				800	800
11	<b>Other Equity</b>				23,487	20,880
12	<b>Earnings per share (of Rs.2 each) : (not annualised for the quarter ended)</b>					
	(a) Basic (Rs.)	1.65	1.81	2.34	6.52	7.57
	(b) Diluted (Rs.)	1.65	1.81	2.34	6.52	7.57

**Notes:**

- The above statement of audited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company"), have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 15 May 2026. The Statutory Auditors have expressed an unmodified opinion on the standalone financial results.
- The standalone figures for the quarter ended 31 March 2026 and quarter ended 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year ended 31 March 2026 and 31 March 2025, respectively and the published year to date standalone figures up to third quarter ended 31 December 2025 and 31 December 2024, respectively which were subjected to a limited review.
- Exceptional items include:**
  - Effective 21 November 2025, the Government of India consolidated multiple existing labour laws into a unified framework comprising four Labour Codes, collectively referred to as the "New Labour Codes". In accordance with Ind AS 19 - Employee Benefits, the impact of such legislative changes is treated as a plan amendment requiring immediate recognition of the resultant past service cost in the standalone statement of profit and loss. The Company has assessed the impact of the changes in line with the Labour Codes draft rules and FAQs. Based on this assessment, the Company has recognised a one-time increase in employee benefit provisions amounting to Rs 32 Mn, which has been presented as an "exceptional item" in the standalone statement of profit and loss for the quarter and year ended 31 March 2026. The Company continues to monitor the finalisation of Central and State rules, as well as Government clarifications on other aspects of the New Labour Codes and will incorporate appropriate accounting treatment based on these developments as required.
  - Balance exceptional items for current and earlier periods / years pertains to valuation of call option under the call option agreements executed by the Company in previous year to acquire a majority equity stake in entities with whom the Company has Operations and Management agreements to operate and manage their hospitals.
- The Audited Standalone Balance sheet and Audited Standalone Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- The Company operates in one single reportable business segment - "Medical and Healthcare services".
- The above Audited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where

For and on behalf of the Board  
**Krishna Institute of Medical Sciences Limited**

Hyderabad  
15 May 2026



Dr. B. Bhaskara Rao  
Managing Director  
DIN: 00008985

Krishna Institute of Medical Sciences Limited  
 Corporate Identity number L55101TG1973PLC040558  
 Registered office: 1-X-31/1 Ministers road, Secunderabad, 500003, Telangana, India  
 Website: www.kimshospitals.com Email: CS@kimshospitals.com Tel: 040 7122 5000

## Audited Standalone Balance Sheet as at 31 March 2026

		(Rupees in millions)	
Particulars		As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	Property, plant and equipment	13,976	7,238
	Capital work-in-progress	1,160	5,303
	Intangible assets	220	208
	Right-of-use assets	1,140	287
	Financial assets		
	(i) Investments	15,228	12,258
	(ii) Loans	6,201	2,886
	(iii) Other financial assets	199	153
	Non-current tax assets (net)	35	-
	Other non-current assets	354	564
	<b>Total Non-current Assets - (1)</b>	<b>38,513</b>	<b>28,897</b>
<b>2</b>	<b>Current Assets</b>		
	Inventories	398	263
	Financial assets		
	(i) Trade receivables	2,784	1,874
	(ii) Cash and cash equivalents	251	261
	(iii) Bank balances other than (iii) above	49	35
	(iv) Loans	261	99
	(v) Other financial assets	325	274
	Other current assets	270	188
	<b>Total Current Assets - (2)</b>	<b>4,338</b>	<b>2,994</b>
<b>3</b>	<b>Total Assets (3) = (1)+(2)</b>	<b>42,851</b>	<b>31,891</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>4</b>	<b>Equity</b>		
	Equity share capital	800	800
	Other equity	23,487	20,880
	<b>Total Equity - (4)</b>	<b>24,287</b>	<b>21,680</b>
<b>5</b>	<b>Non-current liabilities</b>		
	Financial liabilities		
	(i) Borrowings	11,032	5,771
	(ii) Lease liabilities	724	-
	(iii) Other financial liabilities	98	26
	Provisions	255	207
	Other non-current liabilities	241	228
	Deferred tax liabilities (net)	567	392
	<b>Total Non-current liabilities - (5)</b>	<b>12,917</b>	<b>6,624</b>
<b>6</b>	<b>Current liabilities</b>		
	Financial liabilities		
	(i) Borrowings	3,496	1,309
	(ii) Lease liabilities	11	-
	(iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	250	52
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	886	892
	(iv) Other financial liabilities	344	833
	Provisions	181	139
	Other current liabilities	479	346
	Current tax liabilities (net)	-	16
	<b>Total Current liabilities - (6)</b>	<b>5,647</b>	<b>3,587</b>
	<b>Total Equity and Liabilities (7) = (4)+(5)+(6)</b>	<b>42,851</b>	<b>31,891</b>



**Krishna Institute of Medical Sciences Limited**  
 Corporate Identity number L55101TG1973PLC040558  
 Registered office 1-8-31/1 Ministers road Secunderabad, 500003, Telangana, India  
 Website www.kimshospitals.com, Email CS@kimshospitals.com, Tel 040 7122 5000

**Statement of Audited Standalone Cashflows for the year ended 31 March 2026**

(Rupees in millions)

Particulars	For the year ended	
	31-Mar-26	31-Mar-25
	(Audited)	(Audited)
<b>I. Cash flows from operating activities:</b>		
Profit before tax for the year	3,527	4,031
<b>Adjustments for operating activities:</b>		
Depreciation and amortisation expense	861	577
Profit on sale of property, plant and equipment	(7)	(128)
Provision of expected credit loss for trade receivables (including bad debts)	21	81
Guarantee commission income	-	(161)
Rental income	(1)	(1)
Interest income	(506)	(224)
Deferred Government grants income	(35)	-
Interest income on income tax refund	-	(4)
Loss/(gain) on fair valuation of Call option (net)	38	(108)
Gain on mutual funds	(1)	(29)
Finance costs	787	232
<b>Operating cash flows before working capital changes</b>	<b>4,684</b>	<b>4,266</b>
<b>Adjustments for:</b>		
<b>Increase</b>		
- in trade receivables	(931)	(468)
- in inventories	(135)	(42)
- in other financial assets and other assets	(288)	(110)
-increase in trade payables, other financial liabilities, provisions and other liabilities	391	188
<b>Cash generated from operations</b>	<b>3,721</b>	<b>3,834</b>
Income taxes paid, net of refunds	(796)	(898)
<b>Net cash generated from operating activities (1)</b>	<b>2,925</b>	<b>2,936</b>
<b>II. Cash flows from investing activities</b>		
Purchase of property, plant and equipment and other intangible assets, including capital work-in-progress and capital advances	(3,566)	(3,517)
Proceeds from sale of property, plant and equipment	15	459
Investment in subsidiaries	(2,970)	(2,202)
Advance for investment in subsidiary	(54)	-
Investment in mutual funds	(900)	(1,895)
Proceeds from sale of mutual funds	901	2,540
Loans given to subsidiaries	(4,692)	(2,928)
Loans repaid by subsidiaries	1,466	1,147
Redemption of bank deposits (having original maturity of more than three months)	12	12
Investment in bank deposits (having original maturity of more than three months)	(24)	(46)
Rental income received	1	1
Interest received	253	163
<b>Net cash flows used in investing activities (2)</b>	<b>(9,558)</b>	<b>(6,266)</b>
<b>III. Cash flows from financing activities</b>		
Proceeds from long-term borrowings	6,682	3,871
Repayment of long-term borrowings	(791)	(219)
Proceeds from short-term borrowings (net)	1,541	165
Interest paid	(809)	(431)
<b>Net cash flows generated from financing activities (3)</b>	<b>6,623</b>	<b>3,386</b>
Net (decrease)/increase in cash and cash equivalents (1+2+3)	(10)	56
Cash and cash equivalents at the beginning of the year	261	205
<b>Cash and cash equivalents at the end of the year</b>	<b>251</b>	<b>261</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	14	14
Balances with banks		
- On current accounts	237	247
<b>Total</b>	<b>251</b>	<b>261</b>



**Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
Krishna Institute of Medical Sciences Limited

**Report on the audit of the Consolidated Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date consolidated financial results of Krishna Institute of Medical Sciences Limited ("Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended March 31, 2026 and for the year ended March 31, 2026 ("Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements/ financial results/financial information of the subsidiaries and associate, the Statement:

- i. includes the results of the following entities;

S.No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary
11	SPANV Medisearch Lifesciences Private Limited	Subsidiary
12	KIMS Manavata Hospitals Private Limited	Subsidiary
13	Meda Institute of Podiatry Private Limited	Subsidiary
14	Chalasanani Hospitals Private Limited	Subsidiary
15	Kondapur Healthcare Limited	Associate

- ii. are presented in accordance with the requirements of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter ended March 31, 2026 and for the year ended March 31, 2026.



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Consolidated Financial Results” section of our report. We are independent of the Group and its associate in accordance with the ‘Code of Ethics’ issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matter” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

## **Management’s Responsibilities for the Consolidated Financial Results**

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associate in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of their respective companies and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of their respective companies to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are also responsible for overseeing the financial reporting process of their respective companies.

## **Auditor’s Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associate of which we are the independent auditors, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Master Circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

## **Other Matter**

The accompanying Statement includes the audited financial results/statements and other financial information, in respect of:

- Three subsidiaries, whose financial results/statements include total assets of Rs. 4,045 million as at March 31, 2026, total revenues of Rs. 362 million and Rs. 1,112 million, total net loss after tax of Rs. 58 million and Rs. 215 million, total comprehensive loss of Rs. 57 million and Rs. 214 million, for the quarter and the year ended on that date respectively, and net cash outflows of Rs. 41 million for the year ended March 31, 2026, as considered in the Statement which have been audited by their respective independent auditors.
- An associate, whose financial results/statements include Group's share of net profit of Rs. 26 million and Group's share of total comprehensive income of Rs 26 million for the quarter and year ended March 31, 2026, as considered in the Statement whose financial results/financial statements, other financial information have been audited by their respective independent auditors.

The independent auditor's report on the financial statements/financial results/financial information of these entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

**For S.R. Batliboi & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004

*Navneet Rai*

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 26102328HX MUY9758



Place: Hyderabad

Date: May 15, 2026

**Statement of Audited Consolidated Financial Results for the Quarter and year ended ended 31 March 2026**

(Rupees in millions)

	Quarter ended		Year ended	
	31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-25
	(Audited) (Refer note 2)	(Unaudited)	(Audited) (Refer note 2)	(Audited)
<b>1 Income</b>				
(a) Revenue from operations	10,746	9,977	7,969	39,046
(b) Other income	97	52	45	262
<b>Total Income</b>	<b>10,843</b>	<b>10,029</b>	<b>8,014</b>	<b>39,308</b>
<b>2 Expenses</b>				
(a) Purchase of medical consumables, drugs and surgical instruments	2,354	2,112	1,692	8,418
(b) Increase in inventories of medical consumables, drugs and surgical instruments	(26)	(143)	(21)	(329)
(c) Employee benefits expense	1,799	1,763	1,341	6,817
(d) Other expenses	4,554	4,256	2,977	16,120
(e) Finance costs	681	568	267	2,025
(f) Depreciation and amortisation expenses	850	787	576	2,832
<b>Total Expenses</b>	<b>10,212</b>	<b>9,343</b>	<b>6,782</b>	<b>35,883</b>
<b>3 Profit before share of profit from associate (1-2)</b>	<b>631</b>	<b>686</b>	<b>1,232</b>	<b>3,425</b>
<b>4 Share of profit from associate, net of tax</b>	<b>26</b>	<b>-</b>	<b>-</b>	<b>26</b>
<b>5 Profit before tax and exceptional items (3+4)</b>	<b>657</b>	<b>686</b>	<b>1,232</b>	<b>3,451</b>
<b>6 Exceptional items</b>	<b>(109)</b>	<b>-</b>	<b>108</b>	<b>(112)</b>
<b>7 Profit before tax (5+6)</b>	<b>548</b>	<b>686</b>	<b>1,340</b>	<b>3,339</b>
<b>8 Tax expense</b>				
(a) Current tax	348	331	357	1,362
(b) Deferred tax credit	(131)	(164)	(78)	(443)
<b>Total tax expenses (8)</b>	<b>217</b>	<b>167</b>	<b>279</b>	<b>919</b>
<b>9 Profit for the period/year (7-8)</b>	<b>331</b>	<b>519</b>	<b>1,061</b>	<b>2,420</b>
Attributable to:				
Owners of the company	425	534	1,018	2,414
Non controlling interests	(94)	(15)	43	6
<b>10 Other comprehensive income/(loss) for the period/year</b>				
Items that will not be reclassified subsequently to statement of profit and loss				
- Re-measurement gain/(loss) on defined benefit plans	4	-	11	2
- Income tax effect	-	-	(3)	-
<b>Other comprehensive income/(loss), net of tax</b>	<b>4</b>	<b>-</b>	<b>8</b>	<b>2</b>
Attributable to:				
Owners of the company	5	-	7	1
Non controlling interests	-	-	1	-
<b>11 Total comprehensive income (9+10)</b>	<b>335</b>	<b>519</b>	<b>1,069</b>	<b>2,422</b>
Attributable to:				
Owners of the company	428	534	1,025	2,415
Non controlling interests	(93)	(15)	44	7
<b>Total comprehensive income for the period/year</b>	<b>335</b>	<b>519</b>	<b>1,069</b>	<b>2,422</b>
<b>12 Paid up equity share capital (face value of Rs.2 each)</b>				<b>800</b>
<b>13 Other Equity</b>				<b>21,674</b>
<b>14 Earnings per share (of Rs.2 each): (not annualised for the quarter ended)</b>				
(a) Basic (Rs.)	1.06	1.33	2.54	6.03
(b) Diluted (Rs.)	1.06	1.33	2.54	6.03

**Notes:**

- The above statement of audited consolidated financial results of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") and its associate, have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 15 May 2026. The Statutory Auditors have expressed an unmodified opinion on the consolidated financial results.
- The Consolidated figures for the quarter ended 31 March 2026 and quarter ended 31 March 2025 are the balancing figures between the audited Consolidated figures in respect of the full financial year ended 31 March 2026 and 31 March 2025, respectively and the published year to date Consolidated figures up to third quarter ended 31 December 2025 and 31 December 2024, respectively which were subjected to a limited review.
- Exceptional items include:**
  - Effective 21 November 2025, the Government of India consolidated multiple existing labour laws into a unified framework comprising four Labour Codes, collectively referred to as the "New Labour Codes". In accordance with Ind AS 19 - Employee Benefits, the impact of such legislative changes is treated as a plan amendment requiring immediate recognition of the resultant past service cost in the consolidated statement of profit and loss. The Group has assessed the impact of the changes in line with the Labour Codes draft rules and FAQs. Based on this assessment, the Group has recognised a one-time increase in employee benefit provisions amounting to Rs 74 Mn, which has been presented as an "exceptional item" in the consolidated statement of profit and loss for the quarter and year ended 31 March 2026. The Group continues to monitor the finalisation of Central and State rules, as well as Government clarifications on other aspects of the New Labour Codes and will incorporate appropriate accounting treatment based on these developments as required.
  - Balance exceptional items for current and earlier periods / years pertain to valuation of call option under the call option agreements executed by the Group in previous year to acquire a majority equity stake in entities with whom the Group has Operations and Management agreements to operate and manage their hospitals.
- The Audited Consolidated Balance sheet and Audited Consolidated Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- The Group operates in one single reportable business segment - "Medical and Healthcare services".
- The above Audited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.



For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

*Dr. B Bhaskara Rao*  
Managing Director  
DIN: 00008985

**Krishna Institute of Medical Sciences Limited**  
 Corporate Identity number L55101TG1973PLC040558  
 Registered office 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India  
 Website www.kimshospitals.com, Email CS@kimshospitals.com, Tel 040 7122 5000

**Audited Consolidated Balance Sheet as at 31 March 2026**

(Rupees in millions)			
S.No	Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	Property, plant and equipment	41,862	21,988
	Capital work-in-progress	6,062	12,138
	Goodwill	3,386	3,386
	Other intangible assets	570	677
	Right-of-use assets	11,283	7,434
	Investments accounted for using equity method	875	765
	Financial assets		
	(i) Investments	6	6
	(ii) Loans	134	55
	(iii) Other financial assets	778	601
	Deferred tax asset (net)	1,274	599
	Non-current tax assets (net)	550	438
	Other non-current assets	1,433	2,300
	<b>Total Non-current Assets - (1)</b>	<b>68,213</b>	<b>50,387</b>
<b>2</b>	<b>Current Assets</b>		
	Inventories	969	640
	Financial assets		
	(i) Investments	151	220
	(ii) Trade receivables	5,542	3,954
	(iii) Cash and cash equivalents	554	560
	(iv) Bank balances other than (iii) above	193	245
	(v) Loans	722	492
	(vi) Other financial assets	675	485
	Other current assets	568	377
	<b>Total Current Assets - (2)</b>	<b>9,374</b>	<b>6,973</b>
<b>3</b>	<b>Total Assets (3) = (1)+(2)</b>	<b>77,587</b>	<b>57,360</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>4</b>	<b>Equity</b>		
	Equity share capital	800	800
	Other equity	21,674	20,578
	<b>Equity attributable to Shareholders of the company - (4)</b>	<b>22,474</b>	<b>21,378</b>
<b>5</b>	<b>Non-controlling interests - (5)</b>	<b>3,111</b>	<b>2,810</b>
<b>6</b>	<b>Total Equity (6) = (4)+(5)</b>	<b>25,585</b>	<b>24,188</b>
<b>7</b>	<b>Non-current liabilities</b>		
	Financial liabilities		
	(i) Borrowings	26,726	16,542
	(ii) Lease liabilities	9,648	6,331
	(iii) Other financial liabilities	1,494	777
	Provisions	457	335
	Other non-current liabilities	608	357
	Deferred tax liabilities (net)	680	468
	<b>Total Non-current liabilities - (7)</b>	<b>39,613</b>	<b>24,810</b>
<b>8</b>	<b>Current liabilities</b>		
	Financial liabilities		
	(i) Borrowings	5,714	2,567
	(ii) Lease liabilities	441	176
	(iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	534	150
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	2,694	2,541
	(iv) Other financial liabilities	1,900	2,110
	Provisions	326	264
	Other current liabilities	780	538
	Current tax liabilities (net)	-	16
	<b>Total Current liabilities - (8)</b>	<b>12,389</b>	<b>8,362</b>
<b>9</b>	<b>Total Equity and Liabilities (9) = (6)+(7)+(8)</b>	<b>77,587</b>	<b>57,360</b>



Krishna Institute of Medical Sciences Limited  
 Corporate Identity number : L55101TG1973PLC040558  
 Registered office 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India  
 Website www.kimshospitals.com, Email CS@kimshospitals.com, Tel 040 7122 5000

## Statement of Audited Consolidated Cash flows for the year ended 31 March 2026

(Rupees in millions)

Particulars	For the year ended	For the year ended
	31-Mar-26 (Audited)	31-Mar-25 (Audited)
<b>I. Cash flows from operating activities:</b>		
Profit before tax for the year	3,339	5,581
<b>Adjustments for operating activities:</b>		
Depreciation and amortisation expenses	2,832	1,772
Finance costs	2,025	903
Loss/(profit) on sale of property, plant and equipment (net)	5	(109)
Provision of expected credit loss for trade receivables (including bad debts)	97	130
Interest income	(121)	(102)
Deferred Government grants income	(35)	-
Liabilities no longer required written back	(10)	(6)
Gain on mutual funds	(5)	(48)
Rental income	(16)	(7)
Loss/(gain) on fair valuation of Call option (net)	38	(108)
Income on termination of lease	-	(5)
Share of profit from associate	(26)	-
<b>Operating cash flows before working capital changes</b>	<b>8,123</b>	<b>8,001</b>
<b>Adjustments for:</b>		
<b>(Increase)/Decrease</b>		
- in Trade receivables	(1,685)	(934)
- in Inventories	(329)	(133)
- in Other financial assets and other assets	(465)	(322)
Increase in trade payables, other financial liabilities, provisions and other liabilities	974	620
<b>Cash generated from operations</b>	<b>6,618</b>	<b>7,232</b>
Income taxes paid, net of refunds	(1,510)	(1,414)
<b>Net cash generated from operating activities (1)</b>	<b>5,108</b>	<b>5,818</b>
<b>II. Cash flows from investing activities</b>		
Purchase of property, plant and equipment and other intangible assets, including capital work-in-progress and capital advances	(14,279)	(10,089)
Proceeds from sale of property, plant and equipment	150	472
Investment in associate	(84)	(27)
Acquisition of subsidiaries	-	(1,123)
Acquisition of business	-	(634)
Investment in mutual funds	(1,990)	(3,500)
Proceeds from sale of mutual funds	2,064	4,157
Loans given	(864)	(272)
Loans repayment received	555	-
Redemption of bank deposits (having original maturity of more than three months)	105	117
Investment in bank deposits (having original maturity of more than three months)	(287)	(349)
Rental income received	16	7
Interest received	97	79
<b>Net cash used in investing activities (2)</b>	<b>(14,517)</b>	<b>(11,162)</b>
<b>III. Cash flows from financing activities</b>		
Proceeds from long-term borrowings	13,423	8,487
Repayment of long-term borrowings	(2,095)	(837)
Proceeds from short-term borrowings (net)	1,962	288
Issue of preference shares to non-controlling interest	192	64
Issue of shares to non-controlling interest	288	-
Acquisition of non-controlling interest	(1,505)	(942)
Share application money received from non-controlling interest	8	-
Advance paid for acquisition of non-controlling interest	(54)	-
Payment of principal of lease liability	(685)	(131)
Payment of interest on lease liability	(59)	(269)
Interest paid	(2,072)	(1,229)
<b>Net cash flows generated from financing activities (3)</b>	<b>9,403</b>	<b>5,431</b>
<b>Net (decrease)/increase in cash and cash equivalents (1+2+3)</b>	<b>(6)</b>	<b>87</b>
<b>Cash and cash equivalents acquired through business combination</b>	<b>-</b>	<b>4</b>
Cash and cash equivalents at the beginning of the year	560	469
<b>Cash and cash equivalents at the end of the year</b>	<b>554</b>	<b>560</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	29	32
Balances with banks		
- On current accounts	391	461
- In deposit accounts (with original maturity of 3 months or less)	134	67
<b>Total</b>	<b>554</b>	<b>560</b>



Annexure-2

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026.

Sr. No	Particulars	Description
1.	Reason for change viz. appointment, <del>re-appointment,</del> <del>resignation,</del> <del>removal,</del> <del>death</del> or otherwise	Appointment of M/s. Sagar & Associates, Cost Accountants (A peer reviewed firm), as the cost auditors of the Company.
2.	Date of <del>appointment/</del> re-appointment/cessation (as applicable) & term of appointment/re-appointment	Appointed on May 15, 2026 for a term of one year i.e April 1, 2026, to March 31, 2027.
3.	Brief profile (in case of appointment)	<p>M/s. Sagar &amp; Associates is a leading firm of Cost &amp; Management Accountants having diversified activities in Cost and Management Accounting area.</p> <p>The firm consisting of qualified Cost Accountants and has undertaken many assignments in various industries. The firm clients list includes leading and big companies with multiple locations and diversified product portfolio. They have very high exposure to ERP systems as the majority of their clients have SAP &amp; ORACLE.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

**Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026.**

Sr. No	Particulars	Description			
1.	Reason for change viz. appointment, re-appointment, <del>resignation, removal, death</del> or otherwise	Appointment of Mr. Sachin Ashok Salvi as Senior Management Personnel of the Company	Appointment of Mrs. Nagajayanthi J.R as Senior Management Personnel of the Company	Appointment of Mr. Bhaskar Reddy R.K as Senior Management Personnel of the Company	Re-designation of Mr. Adwik Bollineni as Executive & Non independent Director of the Company
2.	Date of <del>appointment/re-appointment/cessation</del> (as applicable) & term of appointment/re-appointment	With effect from 15 <sup>th</sup> May, 2026 i.e. today.			
3.	Brief profile (in case of appointment)	He is a Chartered Accountant with over 21 years of experience in finance, accounting, financial reporting, and regulatory compliance. He has played a key role in managing IPO processes, including financial restatements and due diligence. His expertise spans IndAS, ICDS, ICDR regulations,	She is a Fellow Member of the Institute of Company Secretaries of India. She holds a B.A. (Honours) in Economics from Delhi University, a Law degree from Osmania University, and has completed both a Master's degree and a Doctorate in Financial Management. She with her over 25 years of experience in the fields of Secretarial	He is Chartered Accountant With over 12 years of Experience in managing internal audits, governance reviews, risk assessments, and control evaluations. Skilled in identifying process inefficiencies, strengthening internal controls, improving governance frameworks, and delivering actionable recommendations to management	He is a governing member of the Aditya Educational Society and has transformed Srikakulam's Great Eastern Medical School (GEMS) into Andhra Pradesh's second most sought-after medical college. Under his leadership, GEMS became the first and only Indian institution

		<p>GST, direct and indirect taxation, and regulatory liaison with SEBI, RBI, and tax authorities. He began his career with SD Khanolkar &amp; Co., Mumbai, and later served as Finance Controller and CFO at Thyrocare Group, Navi Mumbai.</p>	<p>practice, Legal affairs, Corporate Finance, and Compliance</p>	<p>for operational and risk optimization. His experience includes 3 years with global consulting firms – Deloitte and BDO – in Risk Advisory and Business Restructuring engagements.</p>	<p>accredited by the Royal College of Surgeons of England for surgical excellence. Driven by his sharp business acumen, GEMS also earned the 2024 Chief Minister's Award as the best hospital in Andhra Pradesh.</p>
4.	<p>Disclosure of relationships between directors (in case of appointment of a director)</p>	<p>Not Applicable</p>	<p>Not Applicable</p>	<p>Not Applicable</p>	<p>He is Son of Dr. B. Bhaskara Rao, CMD and Brother of Dr Abhinay Bollineni, Director &amp; CEO.</p>